Safety and functional enrichment of gut microbiome in healthy subjects consuming a multi-strain fermented milk product: a randomised controlled trial.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 09 2020
Historique:
received: 09 01 2020
accepted: 24 08 2020
entrez: 30 9 2020
pubmed: 1 10 2020
medline: 13 1 2021
Statut: epublish

Résumé

Many clinical studies have evaluated the effect of probiotics, but only a few have assessed their dose effects on gut microbiota and host. We conducted a randomized, double-blind, controlled intervention clinical trial to assess the safety (primary endpoint) of and gut microbiota response (secondary endpoint) to the daily ingestion for 4 weeks of two doses (1 or 3 bottles/day) of a fermented milk product (Test) in 96 healthy adults. The Test product is a multi-strain fermented milk product, combining yogurt strains and probiotic candidate strains Lactobacillus paracasei subsp. paracasei CNCM I-1518 and CNCM I-3689 and Lactobacillus rhamnosus CNCM I-3690. We assessed the safety of the Test product on the following parameters: adverse events, vital signs, hematological and metabolic profile, hepatic, kidney or thyroid function, inflammatory markers, bowel habits and digestive symptoms. We explored the longitudinal gut microbiota response to product consumption and dose, by 16S rRNA gene sequencing and functional contribution by shotgun metagenomics. Safety results did not show any significant difference between the Test and Control products whatever the parameters assessed, at the two doses ingested daily over a 4-week-period. Probiotic candidate strains were detected only during consumption period, and at a significantly higher level for the three strains in subjects who consumed 3 products bottles/day. The global structure of the gut microbiota as assessed by alpha and beta-diversity, was not altered by consumption of the product for four weeks. A zero-inflated beta regression model with random effects (ZIBR) identified a few bacterial genera with differential responses to test product consumption dose compared to control. Shotgun metagenomics analysis revealed a functional contribution to the gut microbiome of probiotic candidates.

Identifiants

pubmed: 32994487
doi: 10.1038/s41598-020-72161-w
pii: 10.1038/s41598-020-72161-w
pmc: PMC7524715
doi:

Substances chimiques

DNA, Bacterial 0
DNA, Ribosomal 0
RNA, Ribosomal, 16S 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

15974

Références

FAO/WHO. Guidelines for the Evaluation of Probiotics in Food (World Health Organization, Geneva, 2002).
Hill, C. et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506. https://doi.org/10.1038/nrgastro.2014.66 (2014).
doi: 10.1038/nrgastro.2014.66 pubmed: 24912386
Liu, Y., Tran, D. Q. & Rhoads, J. M. Probiotics in disease prevention and treatment. J. Clin. Pharmacol. 58(Suppl 10), S164–S179. https://doi.org/10.1002/jcph.1121 (2018).
doi: 10.1002/jcph.1121 pubmed: 30248200 pmcid: 6656559
Sniffen, J. C., McFarland, L. V., Evans, C. T. & Goldstein, E. J. C. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS ONE 13, e0209205. https://doi.org/10.1371/journal.pone.0209205 (2018).
doi: 10.1371/journal.pone.0209205 pubmed: 30586435 pmcid: 6306248
Bi, L.-W., Yan, B.-L., Yang, Q.-Y., Li, M.-M. & Cui, H.-L. Probiotic strategies to prevent necrotizing enterocolitis in preterm infants: A meta-analysis. Pediatr. Surg. Int. 35, 1143–1162. https://doi.org/10.1007/s00383-019-04547-5 (2019).
doi: 10.1007/s00383-019-04547-5 pubmed: 31420743
Suez, J., Zmora, N., Segal, E. & Elinav, E. The pros, cons, and many unknowns of probiotics. Nat. Med. 25, 716–729. https://doi.org/10.1038/s41591-019-0439-x (2019).
doi: 10.1038/s41591-019-0439-x pubmed: 31061539
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 16, 605–616. https://doi.org/10.1038/s41575-019-0173-3 (2019).
doi: 10.1038/s41575-019-0173-3 pubmed: 31296969
Derrien, M. & van Hylckama Vlieg, J. E. T. Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 23, 354–366. https://doi.org/10.1016/j.tim.2015.03.002 (2015).
doi: 10.1016/j.tim.2015.03.002 pubmed: 25840765
Kristensen, N. B. et al. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: A systematic review of randomized controlled trials. Genome Med. 8, 52. https://doi.org/10.1186/s13073-016-0300-5 (2016).
doi: 10.1186/s13073-016-0300-5 pubmed: 27159972 pmcid: 4862129
Veiga, P. et al. Changes of the human gut microbiome induced by a fermented milk product. Sci. Rep. 4, 6328. https://doi.org/10.1038/srep06328 (2014).
doi: 10.1038/srep06328 pubmed: 25209713 pmcid: 4160712
McNulty, N. P. et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci. Transl. 3, 106. https://doi.org/10.1126/scitranslmed.3002701 (2011).
doi: 10.1126/scitranslmed.3002701
Maldonado-Gómez, M. X. et al. Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 20, 515–526. https://doi.org/10.1016/j.chom.2016.09.001 (2016).
doi: 10.1016/j.chom.2016.09.001 pubmed: 27693307
Eloe-Fadrosh, E. A. et al. Functional dynamics of the gut microbiome in elderly people during probiotic consumption. MBio 6, e00231. https://doi.org/10.1128/mBio.00231-15 (2015).
doi: 10.1128/mBio.00231-15 pubmed: 25873374 pmcid: 4453556
Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174, 1388–1405. https://doi.org/10.1016/j.cell.2018.08.041 (2018).
doi: 10.1016/j.cell.2018.08.041 pubmed: 30193112
Archambaud, C. et al. Impact of lactobacilli on orally acquired listeriosis. Proc. Natl. Acad. Sci. U.S.A. 109, 16684–16689. https://doi.org/10.1073/pnas.1212809109 (2012).
doi: 10.1073/pnas.1212809109 pubmed: 23012479 pmcid: 3478606
Crouzet, L. et al. Lactobacillus paracasei CNCM I-3689 reduces vancomycin-resistant Enterococcus persistence and promotes Bacteroidetes resilience in the gut following antibiotic challenge. Sci. Rep. 8, 5098. https://doi.org/10.1038/s41598-018-23437-9 (2018).
doi: 10.1038/s41598-018-23437-9 pubmed: 29572473 pmcid: 5865147
Natividad, J. M. et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat. Commun. 9, 2802–2802. https://doi.org/10.1038/s41467-018-05249-7 (2018).
doi: 10.1038/s41467-018-05249-7 pubmed: 30022049 pmcid: 6052103
Martín, R. et al. The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response. Sci. Rep. 9, 5398. https://doi.org/10.1038/s41598-019-41738-5 (2019).
doi: 10.1038/s41598-019-41738-5 pubmed: 30931953 pmcid: 6443702
Laval, L. et al. Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2–165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes 6, 1–9. https://doi.org/10.4161/19490976.2014.990784 (2015).
doi: 10.4161/19490976.2014.990784 pubmed: 25517879 pmcid: 4615674
Fehlbaum, S. et al. In vitro study of Lactobacillus paracasei CNCM I-1518 in healthy and Clostridioides difficile colonized elderly gut microbiota. Front. Nutr. https://doi.org/10.3389/fnut.2019.00184 (2019).
doi: 10.3389/fnut.2019.00184 pubmed: 31921877 pmcid: 6914822
Merenstein, D. et al. Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: The DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur. J. Clin. Nutr. 64, 669–677. https://doi.org/10.1038/ejcn.2010.65 (2010).
doi: 10.1038/ejcn.2010.65 pubmed: 20485304 pmcid: 2906750
Prodeus, A. et al. Fermented milk consumption and common infections in children attending day-care centers: A randomized trial. J. Pediatr. Gastroenterol. Nutr. 63, 534–543. https://doi.org/10.1097/MPG.0000000000001248 (2016).
doi: 10.1097/MPG.0000000000001248 pubmed: 27168455 pmcid: 5084641
Boge, T. et al. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine 27, 5677–5684. https://doi.org/10.1016/j.vaccine.2009.06.094 (2009).
doi: 10.1016/j.vaccine.2009.06.094 pubmed: 19615959
Hickson, M. et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: Randomised double blind placebo controlled trial. BMJ 335, 80. https://doi.org/10.1136/bmj.39231.599815.55 (2007).
doi: 10.1136/bmj.39231.599815.55 pubmed: 17604300 pmcid: 1914504
Dietrich, C. G., Kottmann, T. & Alavi, M. Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea. World J. Gastroenterol. 20, 15837–15844. https://doi.org/10.3748/wjg.v20.i42.15837 (2014).
doi: 10.3748/wjg.v20.i42.15837 pubmed: 25400470 pmcid: 4229551
Guillemard, E., Tondu, F., Lacoin, F. & Schrezenmeir, J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 103, 58–68. https://doi.org/10.1017/S0007114509991395 (2010).
doi: 10.1017/S0007114509991395 pubmed: 19747410
Guillemard, E., Tanguy, J., Flavigny, A., de la Motte, S. & Schrezenmeir, J. Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial. J. Am. Coll. Nutr. 29, 155–468. https://doi.org/10.1080/07315724.2010.10719882 (2010).
doi: 10.1080/07315724.2010.10719882
Collins, J. W. et al. Fermented dairy products modulate Citrobacter rodentium-induced colonic hyperplasia. J. Infect. Dis. 210, 1029–1041. https://doi.org/10.1093/infdis/jiu205 (2014).
doi: 10.1093/infdis/jiu205 pubmed: 24706936 pmcid: 4157696
Doron, S. & Snydman, D. R. Risk and safety of probiotics. Clin. Infect. Dis. 60(Suppl 2), S129–S134. https://doi.org/10.1093/cid/civ085 (2015).
doi: 10.1093/cid/civ085 pubmed: 25922398 pmcid: 4490230
Hempel, S. et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid. Rep. Technol. Assess. 200, 1–645 (2011).
Scalabrin, D., Harris, C., Johnston, W. H. & Berseth, C. L. Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: A 5-year follow-up. Eur. J. Pediatr. 176, 217–224. https://doi.org/10.1007/s00431-016-2825-4 (2017).
doi: 10.1007/s00431-016-2825-4 pubmed: 27975116
Maldonado-Lobón, J. A. et al. Long-term safety of early consumption of Lactobacillus fermentum CECT5716: A 3-year follow-up of a randomized controlled trial. Pharmacol. Res. 95–96, 12–19. https://doi.org/10.1016/j.phrs.2015.01.006 (2015).
doi: 10.1016/j.phrs.2015.01.006 pubmed: 25697549
Merenstein, D. J. et al. Safety of Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12-supplemented yogurt in healthy adults on antibiotics: A phase I safety study. Gut Microbes 6, 66–77. https://doi.org/10.1080/19490976.2015.1005484 (2015).
doi: 10.1080/19490976.2015.1005484 pubmed: 25569274 pmcid: 4615198
Tan, T. P. et al. Safety of Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12-supplemented yogurt in healthy children. J. Pediatr. Gastroenterol. Nutr. 64, 302–309. https://doi.org/10.1097/MPG.0000000000001272 (2017).
doi: 10.1097/MPG.0000000000001272 pubmed: 28114246 pmcid: 5298889
Ouwehand, A. C. A review of dose-responses of probiotics in human studies. Benef. Microbes 8, 143–151. https://doi.org/10.3920/bm2016.0140 (2017).
doi: 10.3920/bm2016.0140 pubmed: 28008787
Hemmerling, A. et al. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex. Transm. Dis. 36, 564–569. https://doi.org/10.1097/OLQ.0b013e3181a74924 (2009).
doi: 10.1097/OLQ.0b013e3181a74924 pubmed: 19543144 pmcid: 2758081
Ibarra, A., Latreille-Barbier, M., Donazzolo, Y., Pelletier, X. & Ouwehand, A. C. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes 9, 236–251. https://doi.org/10.1080/19490976.2017.1412908 (2018).
doi: 10.1080/19490976.2017.1412908 pubmed: 29227175 pmcid: 6219592
EFSA et al. Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 9: Suitability of taxonomic units notified to EFSA until September 2018. EFSA J. 17, e05555. https://doi.org/10.2903/j.efsa.2019.5555 (2019).
doi: 10.2903/j.efsa.2019.5555
Matsuki, T., Watanabe, K., Fujimoto, J., Takada, T. & Tanaka, R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl. Environ. Microbiol. 70, 7220–7228. https://doi.org/10.1128/aem.70.12.7220-7228.2004 (2004).
doi: 10.1128/aem.70.12.7220-7228.2004 pubmed: 15574920 pmcid: 535136
Coelho, L. P. et al. NG-meta-profiler: Fast processing of metagenomes using NGLess, a domain-specific language. Microbiome 7, 84. https://doi.org/10.1186/s40168-019-0684-8 (2019).
doi: 10.1186/s40168-019-0684-8 pubmed: 31159881 pmcid: 6547473
Li, J. et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834. https://doi.org/10.1038/nbt.2942 (2014).
doi: 10.1038/nbt.2942 pubmed: 24997786
Plaza Oñate, F. et al. MSPminer: Abundance-based reconstitution of microbial pan-genomes from shotgun metagenomic data. Bioinformatics 35, 1544–1552. https://doi.org/10.1093/bioinformatics/bty830 (2019).
doi: 10.1093/bioinformatics/bty830 pubmed: 30252023
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).
doi: 10.1093/nar/28.1.27 pubmed: 102409 pmcid: 102409
Ciccarelli, F. D. et al. Toward automatic reconstruction of a highly resolved tree of life. Science 311, 1283–1287. https://doi.org/10.1126/science.1123061 (2006).
doi: 10.1126/science.1123061 pubmed: 16513982
Mäkeläinen, H., Tahvonen, R., Salminen, S. & Ouwehand, A. C. In vivo safety assessment of two Bifidobacterium longum strains. Microbiol. Immunol. 47, 911–914. https://doi.org/10.1111/j.1348-0421.2003.tb03464.x (2003).
doi: 10.1111/j.1348-0421.2003.tb03464.x pubmed: 14695440
Mego, M. et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer 14, 285–290. https://doi.org/10.1007/s00520-005-0891-7 (2006).
doi: 10.1007/s00520-005-0891-7 pubmed: 16175356
Durlak, J. A. How to select, calculate, and interpret effect sizes. J. Pediatr. Psychol. 34, 917–928. https://doi.org/10.1093/jpepsy/jsp004 (2009).
doi: 10.1093/jpepsy/jsp004 pubmed: 19223279
Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Routledge, Abingdon, 1977).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https://doi.org/10.1186/s13059-014-0550-8 (2014).
doi: 10.1186/s13059-014-0550-8 pubmed: 25516281 pmcid: 25516281
Chen, E. Z. & Li, H. A two-part mixed-effects model for analyzing longitudinal microbiome compositional data. Bioinformatics 32, 2611–2617. https://doi.org/10.1093/bioinformatics/btw308 (2016).
doi: 10.1093/bioinformatics/btw308 pubmed: 27187200 pmcid: 5860434
Kurtz, Z. D. et al. Sparse and compositionally robust Inference of microbial ecological networks. PLoS Comput. Biol. 11, e1004226. https://doi.org/10.1371/journal.pcbi.1004226 (2015).
doi: 10.1371/journal.pcbi.1004226 pubmed: 25950956 pmcid: 4423992
Adouard, N. et al. Toward an accessible and robust in vitro approach to evaluate bacterial viability in the upper gastro-intestinal tract: A gastro-intestinal digestive simulator (GIDS) combined with alternative methods to plating. J. Funct. Foods 59, 30–39. https://doi.org/10.1016/j.jff.2019.05.026 (2019).
doi: 10.1016/j.jff.2019.05.026
Larsen, C. N. et al. Dose–response study of probiotic bacteria Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur. J. Clin. Nutr. 60, 1284–1293. https://doi.org/10.1038/sj.ejcn.1602450 (2006).
doi: 10.1038/sj.ejcn.1602450 pubmed: 16721394
Jones, M. L., Martoni, C. J., Tamber, S., Parent, M. & Prakash, S. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: A randomized, placebo-controlled, double-blind study. Food Chem. Toxicol. 50, 2216–2223. https://doi.org/10.1016/j.fct.2012.03.010 (2012).
doi: 10.1016/j.fct.2012.03.010 pubmed: 22425689
Firmesse, O., Mogenet, A., Bresson, J. L., Corthier, G. & Furet, J. P. Lactobacillus rhamnosus R11 consumed in a food supplement survived human digestive transit without modifying microbiota equilibrium as assessed by real-time polymerase chain reaction. J. Mol. Microbiol. Biotechnol. 14, 90–99. https://doi.org/10.1159/000106087 (2008).
doi: 10.1159/000106087 pubmed: 17957115
Bonetti, A., Morelli, L. & Campominosi, E. Assessment of the persistence in the human intestinal tract of two probiotic lactobacilli Lactobacillus salivarius I 1794 and Lactobacillus paracasei I 1688. Microb. Ecol. Health Dis. 14, 229–233. https://doi.org/10.1080/08910600310002118 (2002).
doi: 10.1080/08910600310002118
Fujimoto, J., Matsuki, T., Sasamoto, M., Tomii, Y. & Watanabe, K. Identification and quantification of Lactobacillus casei strain Shirota in human feces with strain-specific primers derived from randomly amplified polymorphic DNA. Int. J. Food Microbiol. 126, 210–215. https://doi.org/10.1016/j.ijfoodmicro.2008.05.022 (2008).
doi: 10.1016/j.ijfoodmicro.2008.05.022 pubmed: 18573558
Saxelin, M. et al. Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese. Int. J. Food Microbiol. 144, 293–300. https://doi.org/10.1016/j.ijfoodmicro.2010.10.009 (2010).
doi: 10.1016/j.ijfoodmicro.2010.10.009 pubmed: 21074284
Lahti, L. et al. Associations between the human intestinal microbiota, Lactobacillus rhamnosus GG and serum lipids indicated by integrated analysis of high-throughput profiling data. PeerJ 1, e32. https://doi.org/10.7717/peerj.32 (2013).
doi: 10.7717/peerj.32 pubmed: 23638368 pmcid: 3628737
McFarland, L. V. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: A systematic review. BMJ Open 4, e005047–e005047. https://doi.org/10.1136/bmjopen-2014-005047 (2014).
doi: 10.1136/bmjopen-2014-005047 pubmed: 25157183 pmcid: 4156804
Derrien, M., Alvarez, A.-S. & de Vos, W. M. The gut microbiota in the first decade of life. Trends Microbiol. 27, 997–1010. https://doi.org/10.1016/j.tim.2019.08.001 (2019).
doi: 10.1016/j.tim.2019.08.001 pubmed: 31474424
Levy, R. & Borenstein, E. Metabolic modeling of species interaction in the human microbiome elucidates community-level assembly rules. Proc. Natl. Acad. Sci. U.S.A. 110, 12804–12809. https://doi.org/10.1073/pnas.1300926110 (2013).
doi: 10.1073/pnas.1300926110 pubmed: 23858463 pmcid: 3732988
Oozeer, R. et al. Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk. Appl. Environ. Microbiol. 72, 5615–5617. https://doi.org/10.1128/aem.00722-06 (2006).
doi: 10.1128/aem.00722-06 pubmed: 16885316 pmcid: 1538725

Auteurs

Anne-Sophie Alvarez (AS)

Danone Nutricia Research, Palaiseau, France.

Julien Tap (J)

Danone Nutricia Research, Palaiseau, France.

Isabelle Chambaud (I)

Danone Nutricia Research, Palaiseau, France.

Stéphanie Cools-Portier (S)

Danone Nutricia Research, Palaiseau, France.

Laurent Quinquis (L)

Danone Nutricia Research, Palaiseau, France.

Pierre Bourlioux (P)

Faculty of Pharmacy - Paris-Sud University, Chatenay-Malabry, France.

Philippe Marteau (P)

APHP, Sorbonne Université - INSERM-ERL 1157 - UMR7203, Hôpital Tenon, Paris, France.

Eric Guillemard (E)

Danone Nutricia Research, Palaiseau, France.

Juergen Schrezenmeir (J)

Clinical Research Center Kiel, Kiel Innovation and Technology Center, Schauenburgerstr., Kiel, Germany.

Muriel Derrien (M)

Danone Nutricia Research, Palaiseau, France. muriel.derrien@danone.com.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH